References
- Lau J, Shrestha P, Shaina Ng J, Jianlin Wong G, Legido-Quigley H, Tan KK. Qualitative factors influencing breast and cervical cancer screening in women: A scoping review. Prev Med Rep. 2022;27:101816. https://doi.org/10.1016/j.pmedr.2022.101816 PMid:35656228
- Cserni B, Bori R, Csörgő E, Oláh-Németh O, Pancsa T, Sejben A, et al. The additional value of ONEST (Observers Needed to Evaluate Subjective Tests) in assessing reproducibility of oestrogen receptor, progesterone receptor, and Ki67 classification in breast cancer. Virchows Arch. 2021;479(6):1101-9. https://doi.org/10.1007/s00428-021-03172-9 PMid:34415429
- Turner BM, Katerji H, Zhang H, Hicks DG. Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach. Hum Pathol Rep. 2021;26:300574. https://doi.org/10.1016/j.hpr.2021.300574
- Finkelman BS, Zhang H, Hicks DG, Turner BM. The evolution of Ki-67 and breast carcinoma: Past observations, present directions, and future considerations. Cancers (Basel). 2023;15(3):808. https://doi.org/10.3390/cancers15030808 PMid:36765765
- Yadav S, Zhou S, He B, Du Y, Garmire LX. Deep learning and transfer learning identify breast cancer survival subtypes from single-cell imaging data. Commun Med (Lond). 2023;3(1):187. https://doi.org/10.1038/s43856-023-00414-6 PMid:38114659
- Höller A, Nguyen-Sträuli BD, Frauchiger-Heuer H, Ring A. Diagnostic and prognostic biomarkers of luminal breast cancer: Where are we now? Breast Cancer (Dove Med Press). 2023;15:525-40.
- Kanyılmaz G, Yavuz BB, Aktan M, Karaağaç M, Uyar M, Fındık S. Prognostic importance of Ki-67 in breast cancer and its relationship with other prognostic factors. Eur J Breast Health. 2019;15(4):256-261. https://doi.org/10.5152/ejbh.2019.4778 PMid:31620685
- Zhang H, Niu S, Chen H, Wang L, Wang X, Wu Y, et al. Radiomics signatures for predicting the Ki-67 level and HER-2 status based on bone metastasis from primary breast cancer. Front Cell Dev Biol. 2023;11:1220320. https://doi.org/10.3389/fcell.2023.1220320 PMid:38264355
- Walker RA. Prognostic and Predictive Factors in Breast Cancer. New York: Informa Health Care; 2003:8-10. https://doi.org/10.1177/11782234241255211 PMid:38779417
- Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: A large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157(2):363-71. https://doi.org/10.1007/s10549-016-3817-9 PMid:27155668
- Esmat E, Haidary AM, Saadaat R, Rizvi SN, Aleena S, Haidari M, et al. Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: A cross-sectional study in a tertiary care hospital, Kabul, Afghanistan. BMC Cancer. 2024;24(1):388. https://doi.org/10.1186/s12885-024-12129-5 PMid:38539179
- Hu Q, Hu Y, Ai H, Xia L, Liu R, Ai T. Pre-operative MRI in evaluating pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer: A study focused on influencing factors of baseline clinical-pathological and imaging features. Front Oncol. 2024;14:1366613. https://doi.org/10.3389/fonc.2024.1366613 PMid:38826784
- Liang Q, Ma D, Gao RF, Yu KD. Effect of Ki-67 Expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep. 2020;10(1):7648. https://doi.org/10.1038/s41598-020-64523-1 PMid:32376868
- Niță I, Nițipir C, Toma ȘA, Limbău AM, Pîrvu E, Bădărău IA, et al. Histological aspects and quantitative assessment of Ki67 as prognostic factors in breast cancer patients: Result from a single-center, cross sectional study. Medicina (Kaunas). 2020;56(11):600. https://doi.org/10.3390/medicina56110600 PMid:33182401
- Rewcastle E, Skaland I, Gudlaugsson E, Fykse SK, Baak JP, Janssen EA. The Ki67 dilemma: investigating prognostic cutoffs and reproducibility for automated Ki67 scoring in breast cancer. Breast Cancer Res Treat. 2024;207(1):1-12. https://doi.org/10.1007/s10549-024-07352-4 PMid:38797793
- Sun XB, Liu WW, Wang B, Yang ZP, Tang HZ, Lu S, et al. Correlations between serum lipid and Ki-67 levels in different breast cancer molecular subcategories. Oncol Lett. 2023;25(2):53. https://doi.org/10.3892/ol.2022.13639 PMid:36644143
- Liang Q, Ma D, Gao RF, Yu KD. Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep. 2020;10(1):7648. https://doi.org/10.1038/s41598-020-64523-1 PMid:32376868
- Nielsen TO, Leung SC, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast cancer: Updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113(7):808-19. https://doi.org/10.1093/jnci/djaa201 PMid:33369635
- de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504-13. https://doi.org/10.1038/sj.bjc.6603756 PMid:17453008
- Alco G, Bozdogan A, Selamoglu D, Pilanci KN, Tuzlali S, Ordu C, et al. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. Oncol Lett. 2015;9(3):1046-1054. https://doi.org/10.3892/ol.2015.2852 PMid:25663855
- Wang S, Zhang Q, Zhang T, Mao X. Invasive papillary carcinoma of the breast: A case report. Oncol Lett. 2024;28(1):300. https://doi.org/10.3892/ol.2024.14433 PMid:38765791
- Oshiro C, Yamasaki M, Noda Y, Nishimae A, Takahashi H, Inaji H. Comparative evaluation of nuclear and histological grades as prognostic factors for invasive breast cancer. Breast Cancer. 2020;27(5):947-53. https://doi.org/10.1007/s12282-020-01093-0 PMid:32297249
- Roudini K, Mirzania M, Yavari T, Seyyedsalehi MS, Nahvijou A, Zebardast J, et al. Neoadjuvant chemotherapy in patients with HER2-negative breast cancer: A report from clinical breast cancer registry of Iran. Arch Iran Med. 2024;27(4):206-15. https://doi.org/10.34172/aim.2024.30 PMid:38685847
- Schwartz AM, Henson DE, Chen D, Rajamarthandan S. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program. Arch Pathol Lab Med. 2014;138(8):1048-52. https://doi.org/10.5858/arpa.2013-0435-OA PMid:25076293
- Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153-8. https://doi.org/10.1200/JCO.2007.15.5986 PMid:18490649
- Bruno F, Arcuri D, Vozzo F, Malvaso A, Montesanto A, Maletta R. Expression and signaling pathways of nerve growth factor (NGF) and Pro-NGF in breast cancer: A systematic review. Curr Oncol. 2022;29(11):8103-20. https://doi.org/10.3390/curroncol29110640 PMid:36354700
- Boers J, Eisses B, Zwager MC, Van Geel JJ, Bensch F, De Vries EF, et al. Correlation between histopathological prognostic tumor characteristics and [18F]FDG uptake in corresponding metastases in newly diagnosed metastatic breast cancer. Diagnostics (Basel). 2024;14(4):416. https://doi.org/10.3390/diagnostics14040416 PMid:38396455
- Witt BL, Tollefsbol TO. Molecular, cellular, and technical aspects of breast cancer cell lines as a foundational tool in cancer research. Life (Basel). 2023;13(12):2311. https://doi.org/10.3390/life13122311 PMid:38137912
- Ferraguti G, Terracina S, Tarani L, Fanfarillo F, Allushi S, Caronti B, et al. Nerve growth factor and the role of inflammation in tumor development. Curr Issues Mol Biol. 2024;46(2):965-89. https://doi.org/10.3390/cimb46020062 PMid:38392180
- Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, et al. (2015). High Ki-67 expression and low progesterone receptor expression could independently lead to a worse prognosis for postmenopausal patients with estrogen receptor-positive and HER2-negative breast cancer. Clin Breast Cancer, 15(3), 204-211. https://doi.org/10.1016/j.clbc.2014.12.007 PMid:25600243